MedPath

Efficacy and safety of Glecaprevir/Pibrentasvir plus Ribavirin in Patients who failed Direct-acting antivirals; DAAs with chronic hepatitis C

Not Applicable
Conditions
chronic hepatitis C
Registration Number
JPRN-UMIN000031615
Lead Sponsor
Tokai University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1) Decompensated cirrhosis(jaundice,refractory ascites,hepatic encephalopathy,esophageal varices,spontaneous bacterial peritonitis) 2) Child-Pugh >6 at screening 3) Patients during treatment regardless of any type of cancer 4) Pregnancy or possible pregnancy and breast feeding 5) Patients with severe heart disease 6) Patients with haemoglobinopathies 7) The patients who meets even one any of the following, neutrophils less than 750 /mm3, platelet counts less than <50000 /mm3, Hb less than 10 g/dl 8) Patients with impaired renal function with chronic kidney failure or creatinine clearance less than 50 ml/min 9) Patient with severe mental diseases such as severe depression, the suicide consideration 10)Patients who cannot keep 6-month contraception after in the dosage and the dosage in the male patients that a partner may become pregnant 11)Patients who was judged to be inappropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath